Alvarez R D, Soong S J, Kinney W K, Reid G C, Schray M F, Podratz K C, Morley G W, Shingleton H M
University of Alabama, Birmingham 35294.
Gynecol Oncol. 1989 Nov;35(2):130-5. doi: 10.1016/0090-8258(89)90029-2.
In a retrospective study conducted at the University of Alabama at Birmingham, the University of Michigan, and the Mayo Clinic, 185 patients with previously untreated FIGO stage IB and IIA squamous cell carcinoma of the cervix were found to have nodal metastasis at the time of radical hysterectomy and pelvic lymphadenectomy. Of these patients, 103 received adjuvant pelvic irradiation. Cancer recurred in 76 patients; the median time to recurrence was 3.1 years. The prognostic significance of patient age, clinical stage, lesion diameter, number and location of nodal metastases, and use of adjuvant radiation therapy was determined by multivariate analysis. Only patient age (P = 0.0006), lesion diameter (P less than 0.0001), and number of nodal metastases (P = 0.0004) were noted to be significant factors in determining overall survival. Rates of recurrence were also related to these factors. Employment of these significant variables led to identification of four risk groups. In general, patients with small cervical lesions (diameter less than 1 cm) and no more than two nodes with metastases fell into the low-risk category; those patients with large cervical lesions (diameter greater than 4 cm) and more than two involved nodes fell into the high-risk category. All other patients were categorized into intermediate-risk groups. Ten-year survival was 92% in the low-risk group (n = 13), 70% in the low-intermediate-risk group (n = 66), 56% in the high-intermediate-risk group (n = 66), and 13% in the high-risk group (n = 20). This risk group classification identifies subgroups of early-stage cervical carcinoma patients found to have nodal metastasis at the time of radical hysterectomy that warrant appropriately selected adjuvant therapy.
在阿拉巴马大学伯明翰分校、密歇根大学和梅奥诊所进行的一项回顾性研究中,185例先前未经治疗的国际妇产科联盟(FIGO)IB期和IIA期宫颈鳞状细胞癌患者在根治性子宫切除术和盆腔淋巴结清扫时被发现有淋巴结转移。这些患者中,103例接受了辅助盆腔放疗。76例患者出现癌症复发;复发的中位时间为3.1年。通过多变量分析确定了患者年龄、临床分期、病变直径、淋巴结转移的数量和位置以及辅助放疗的使用等因素的预后意义。仅患者年龄(P = 0.0006)、病变直径(P < 0.0001)和淋巴结转移数量(P = 0.0004)被认为是决定总生存的重要因素。复发率也与这些因素有关。使用这些重要变量导致识别出四个风险组。一般来说,宫颈病变小(直径小于1 cm)且转移淋巴结不超过两个的患者属于低风险类别;宫颈病变大(直径大于4 cm)且受累淋巴结超过两个的患者属于高风险类别。所有其他患者被归类为中风险组。低风险组(n = 13)的10年生存率为92%,低-中风险组(n = 66)为70%,高-中风险组(n = 66)为56%,高风险组(n = 20)为13%。这种风险组分类识别出了在根治性子宫切除术时被发现有淋巴结转移的早期宫颈癌患者亚组,这些亚组需要进行适当选择的辅助治疗。